Nurix Therapeutics, Inc. NRIX Available-for-Sale Debt Securities
Available-for-Sale Debt Securities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s available-for-sale debt securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s available-for-sale debt securities?
- Nurix Therapeutics, Inc. (NRIX) reported available-for-sale debt securities of $469.54M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s available-for-sale debt securities changed year-over-year?
- Nurix Therapeutics, Inc.'s available-for-sale debt securities decreased by 0.9% year-over-year, from $473.76M to $469.54M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s available-for-sale debt securities?
- Over 2 years (2023 to 2025), Nurix Therapeutics, Inc.'s available-for-sale debt securities has grown at a 21.8% compound annual growth rate (CAGR), from $233.28M to $345.98M.
- What does available-for-sale debt securities mean?
- This represents the fair value of debt securities held by the company that are not classified as trading or held-to-maturity. These assets provide liquidity and yield on excess cash while remaining available for sale to support operational or strategic capital needs.